SRX 0.00% 13.3¢ sierra rutile holdings limited

good biotech with significant upside potential

  1. 92 Posts.
    Please do your own dd...

    Neuren Pharmaceuticals Announces Glypromate Trial Recruits 100th Patient
    Thursday January 17, 2008, 9:32 am

    Original Announcement: Glypromate trial recruits 100th patient

    Neuren Pharmaceuticals announced that its Phase III clinical trial with lead compound Glypromate, in development to reduce cognitive impairment following cardiac surgery, has recruited its 100th patient. This is in line with the trial's objective of completing enrolment by December 2008, as almost all sites are now recruiting. The Data Safety Monitoring Committee will review the patient data of these 100 patients and again at 300 patients in mid-2008.


    Neuren Pharma ( NEU.AX)
    Marketcap: only 23 million A$
    Price: 0,16 A$

    News
    http://au.finance.yahoo.com/q/aca?s=NEU.AX

    Awesome Pipeline :

    Glypromate MCI in CABG Phase 3 ongoing
    Motiva Post-stroke-Apathy Phase 2b
    NNZ-2566 Severe TBI(traumatic brain injury)Phase 2a
    NNZ-2566 Mild/Mod TBI Phase 2


    Clinical development update 4 Dec 2007:
    http://www.neurenpharma.com/images/NEU%20Clinical%20Trials%20Update%20Dec%202007.pdf


    Presentation 3 Dec 2007:
    http://www.neurenpharma.com/images/Neuren%20AU%20Presentation%20Dec%202007.pdf


    Homepage:
    http://www.neurenpharma.com/

    Taylor Collison
    http://preset.sphilo.com/neuren/images/NEU%200708%20-%20Hamilton.pdf


    By the end 1Q CY08, we expect Neuren to be running four major
    efficacy trials; namely three Phase 2 trials for NNZ-2566 in
    mild/moderate and severe TBI and Motiva� in post stroke abulia/
    depression coupled with the current Phase 3 trial for Glypromate� in
    CABG. All indications potentially provide Neuren with first to market,
    billion dollar opportunities. With a current market cap of $40.2m, Neuren
    remains a solid value proposition in the sector, where FDA INDs for mid
    to late stage clinical trials continues to remain a vexing proposition. We
    maintain our Speculative Buy recommendation and price target of $1.30,
    though expect to make changes to our valuation model once the
    acquisition has closed, which we expect during the current Q.
 
watchlist Created with Sketch. Add SRX (ASX) to my watchlist
(20min delay)
Last
13.3¢
Change
0.000(0.00%)
Mkt cap ! $56.24M
Open High Low Value Volume
13.0¢ 13.5¢ 13.0¢ $109.3K 836.0K

Buyers (Bids)

No. Vol. Price($)
3 365703 13.0¢
 

Sellers (Offers)

Price($) Vol. No.
13.5¢ 812922 5
View Market Depth
Last trade - 15.53pm 28/06/2024 (20 minute delay) ?
SRX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.